Skip to navigation Skip to content



Results Announced from a Phase III Trial of Laquinimod in Relapsing MS – Trial in Primary Progressive MS Continues

May 10, 2017

The results of a phase III trial of the experimental oral therapy laquinimod show that it did not meet the primary endpoint of slowing progression better than inactive placebo among more than 2000 people with relapsing-remitting MS. The results of this CONCERTO study were announced in a May 5, 2017 press release from Teva Pharmaceutical Industries Ltd. and Active Biotech.
Laquinimod is an immune-modulating compound believed to affect the immune attack on the brain and spinal cord in MS. In the CONCERTO study, some secondary and exploratory endpoints did improve, including slowed brain atrophy (shrinkage), increased time to first relapse, and reduced relapse rates and disease activity on MRI scans. Adverse events in the laquinimod group included headache, nasal inflammation, back pain, and joint pain. Complete data from the trial will be presented at a future medical meeting and published in a scientific journal.
Teva announced that it has no plans to study this drug further in relapsing-remitting MS, but a study is still ongoing  in primary progressive MS.

About Multiple Sclerosis

Multiple sclerosis is an unpredictable, often disabling disease of the central nervous system that disrupts the flow of information within the brain, and between the brain and body. Symptoms range from numbness and tingling to blindness and paralysis. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are leading to better understanding and moving us closer to a world free of MS. Most people with MS are diagnosed between the ages of 20 and 50, with at least two to three times more women than men being diagnosed with the disease. MS affects more than 2.3 million people worldwide.